George Abraham
Symptomatic, non-hospitalized patients with coronavirus disease-2019 (COVID-19) who are at high risk of progressing to severe disease are treated with nirmatrelvir-ritonavir (NMVr). COVID-19 adverse events are more likely to occur in people who have cardiovascular risk factors as well as cardiovascular disease. As a result, they are more likely to receive NMVr. The pharmaceutical enhancer in NMVr, ritonavir, affects the P-glycoprotein pump and is an inhibitor of the CYP450 pathway's enzymes, particularly CYP3A4 and, to a lesser extent, CYP2D6. It is possible for NMVr to interact significantly with medications commonly used to treat cardiovascular conditions, which could result in severe side effects. It is essential to be aware of such interactions and to take preventative measures. In this survey, we examine potential medication drug communications among NMVr and regularly utilized cardiovascular prescriptions in light of their pharmacokinetics and pharmacodynamic properties.
分享此文章
English 
Spanish 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 